Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DMRA NASDAQ:KALV NASDAQ:MLTX NASDAQ:XFOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMRADamora Therapeutics, Inc. Common Stock$29.98$23.87$2.45▼$38.33$1.85B1.46905,185 shs760,871 shsKALVKalVista Pharmaceuticals$27.00$26.27$9.83▼$27.00$1.44B-0.123.07 million shsN/AMLTXMoonLake Immunotherapeutics$18.95$18.33$5.95▼$62.75$1.40B1.041.36 million shs1.39 million shsXFORX4 Pharmaceuticals$4.13$4.08$1.35▼$4.83$389.54M0.351.04 million shs678,917 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMRADamora Therapeutics, Inc. Common Stock0.00%+18.92%+34.38%+19.49%+761.49%KALVKalVista Pharmaceuticals0.00%0.00%+0.19%+35.68%+129.20%MLTXMoonLake Immunotherapeutics0.00%-4.77%+1.23%+9.16%-60.41%XFORX4 Pharmaceuticals0.00%+2.74%+2.99%-2.59%+108.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMRADamora Therapeutics, Inc. Common Stock$29.98$23.87$2.45▼$38.33$1.85B1.46905,185 shs760,871 shsKALVKalVista Pharmaceuticals$27.00$26.27$9.83▼$27.00$1.44B-0.123.07 million shsN/AMLTXMoonLake Immunotherapeutics$18.95$18.33$5.95▼$62.75$1.40B1.041.36 million shs1.39 million shsXFORX4 Pharmaceuticals$4.13$4.08$1.35▼$4.83$389.54M0.351.04 million shs678,917 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMRADamora Therapeutics, Inc. Common Stock0.00%+18.92%+34.38%+19.49%+761.49%KALVKalVista Pharmaceuticals0.00%0.00%+0.19%+35.68%+129.20%MLTXMoonLake Immunotherapeutics0.00%-4.77%+1.23%+9.16%-60.41%XFORX4 Pharmaceuticals0.00%+2.74%+2.99%-2.59%+108.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDMRADamora Therapeutics, Inc. Common Stock 2.91Moderate Buy$42.4341.52% UpsideKALVKalVista Pharmaceuticals 2.22Hold$30.6013.33% UpsideMLTXMoonLake Immunotherapeutics 2.41Hold$24.2127.78% UpsideXFORX4 Pharmaceuticals 2.50Moderate Buy$9.38127.00% UpsideCurrent Analyst Ratings BreakdownLatest XFOR, DMRA, MLTX, and KALV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026MLTXMoonLake Immunotherapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$24.00 ➝ $29.006/23/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/18/2026DMRADamora Therapeutics, Inc. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/12/2026DMRADamora Therapeutics, Inc. Common Stock WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$35.006/11/2026DMRADamora Therapeutics, Inc. Common Stock HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.006/9/2026MLTXMoonLake Immunotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.006/8/2026DMRADamora Therapeutics, Inc. Common Stock TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/8/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.006/4/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/2/2026XFORX4 Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$12.005/28/2026DMRADamora Therapeutics, Inc. Common Stock WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$35.00(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDMRADamora Therapeutics, Inc. Common StockN/AN/AN/AN/A($110.11) per shareN/AKALVKalVista Pharmaceuticals$1.43M1,008.07N/AN/A$2.71 per share9.96MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$4.27 per shareN/AXFORX4 Pharmaceuticals$35.11M11.09N/AN/A$2.13 per share1.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDMRADamora Therapeutics, Inc. Common Stock-$209.84M-$5.58N/AN/AN/AN/A-428.30%-114.62%8/5/2026 (Estimated)KALVKalVista Pharmaceuticals-$109.52M-$3.46N/A36.00N/AN/A-341.44%-111.94%8/13/2026 (Estimated)MLTXMoonLake Immunotherapeutics-$227.32M-$3.87N/AN/AN/AN/A-85.15%-60.52%8/4/2026 (Estimated)XFORX4 Pharmaceuticals-$79.20M-$4.54N/AN/AN/A-1,106.30%-94.90%-48.09%8/6/2026 (Estimated)Latest XFOR, DMRA, MLTX, and KALV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026KALVKalVista Pharmaceuticals-$0.3763-$0.43-$0.0538-$0.43$39.03 million$40.86 million5/13/2026Q1 2026DMRADamora Therapeutics, Inc. Common Stock-$0.3878-$0.62-$0.2322-$0.62N/AN/A5/11/2026Q1 2026MLTXMoonLake Immunotherapeutics-$0.91-$0.98-$0.07-$0.98N/AN/A5/6/2026Q1 2026XFORX4 Pharmaceuticals-$0.20-$0.16+$0.04-$0.16$3.20 million$2.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDMRADamora Therapeutics, Inc. Common StockN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/AXFORX4 PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDMRADamora Therapeutics, Inc. Common StockN/A22.4922.48KALVKalVista Pharmaceuticals8.185.175.10MLTXMoonLake Immunotherapeutics0.398.608.60XFORX4 Pharmaceuticals0.4510.189.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDMRADamora Therapeutics, Inc. Common Stock14.20%KALVKalVista PharmaceuticalsN/AMLTXMoonLake Immunotherapeutics93.85%XFORX4 Pharmaceuticals72.03%Insider OwnershipCompanyInsider OwnershipDMRADamora Therapeutics, Inc. Common Stock0.40%KALVKalVista Pharmaceuticals4.30%MLTXMoonLake Immunotherapeutics12.02%XFORX4 Pharmaceuticals1.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDMRADamora Therapeutics, Inc. Common Stock4061.55 million61.31 millionNo DataKALVKalVista Pharmaceuticals10053.24 million50.95 millionOptionableMLTXMoonLake Immunotherapeutics273.61 million64.77 millionOptionableXFORX4 Pharmaceuticals8094.32 million93.25 millionNo DataXFOR, DMRA, MLTX, and KALV HeadlinesRecent News About These CompaniesX4 Pharmaceuticals (NASDAQ:XFOR) CFO David Kirske Sells 8,543 SharesJuly 2 at 6:22 AM | insidertrades.comX4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of DirectorsJuly 1, 2026 | globenewswire.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Recommendation of "Moderate Buy" by AnalystsJune 30, 2026 | americanbankingnews.comContrasting X4 Pharmaceuticals (NASDAQ:XFOR) & Helix Biopharma (OTCMKTS:HBPCF)June 30, 2026 | americanbankingnews.comWhy X4 Pharmaceuticals, Inc.’s (XFOR) Stock Is Up 5.01%June 26, 2026 | aaii.comAX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comX4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceMay 27, 2026 | globenewswire.comHow The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU ProgressMay 21, 2026 | finance.yahoo.comBears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' NowMay 20, 2026 | zacks.comX4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should KnowMay 18, 2026 | zacks.comHere is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy NowMay 15, 2026 | finance.yahoo.comHere is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy NowMay 14, 2026 | insidermonkey.comGuggenheim Sticks to Their Buy Rating for X4 Pharmaceuticals (XFOR)May 11, 2026 | theglobeandmail.comX4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2026 | zacks.comX4 Pharmaceuticals Reports Positive Updates on 4WARD Phase 3 Trial and European Commission Approval for XOLREMDI®May 6, 2026 | quiverquant.comQX4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6, 2026 | globenewswire.comX4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European UnionApril 29, 2026 | globenewswire.comOne X4 Pharmaceuticals Insider Raised Their Stake In The Previous YearApril 9, 2026 | finance.yahoo.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2026 | globenewswire.comX4 Pharmaceuticals (XFOR) price target increased by 25.00% to 11.90March 27, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXFOR, DMRA, MLTX, and KALV Company DescriptionsDamora Therapeutics, Inc. Common Stock NASDAQ:DMRA$29.98 0.00 (0.00%) As of 07/2/2026 04:00 PM EasternGalecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.KalVista Pharmaceuticals NASDAQ:KALV$27.00 0.00 (0.00%) As of 06/12/2026KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.MoonLake Immunotherapeutics NASDAQ:MLTX$18.95 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$18.93 -0.02 (-0.08%) As of 07/2/2026 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.X4 Pharmaceuticals NASDAQ:XFOR$4.13 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$4.13 0.00 (0.00%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
